Cephalon Announces Executive Appointment; Jeff Myers Named Vice President of Government Affairs

FRAZER, Pa. and WASHINGTON, July 13 /PRNewswire/ — Cephalon, Inc. today announced the appointment of Jeff Myers to Vice President, Government Affairs. In this position, he will develop policy positions and manage the company’s advocacy efforts with the Congress and federal agencies, as well as coordinate the company’s participation in industry trade associations such as the Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers Association. He is based in Cephalon’s new Washington, D.C. office.

Myers has more than 15 years of government relations experience and has worked on healthcare policy for the past 12 years. Most recently, he served as Director of Government Relations at BiogenIdec, where he was responsible for representing the company before the legislative, executive, and administrative branches of the federal government. His experience also includes roles of increasing responsibility as legislative assistant and legislative director for several members of the U.S. House of Representatives.

“Jeff’s work at the intersection of healthcare, public policy, and politics is truly an asset to Cephalon,” said John E. Osborn, Senior Vice President and General Counsel. “His extensive knowledge of the prescription drug reimbursement process will be especially important as Cephalon and other biopharmaceutical companies are affected by the implementation next year of the Medicare outpatient prescription drug benefit program.”

   Myers holds an MBA from the Fuqua School of Business at Duke University.    Cephalon, Inc.  

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products to treat sleep and neurological disorders, cancer and pain.

Cephalon currently employs more than 2,300 people in the United States and Europe. U.S. sites include corporate headquarters in Frazer, Pennsylvania, research and development in West Chester, Pennsylvania, manufacturing facilities in Salt Lake City, Utah, and R&D and manufacturing in suburban Minneapolis, Minnesota. Major European offices are in Guildford, England, Martinsried, Germany, and in Maisons-Alfort, France.

The company currently markets three proprietary products in the United States: PROVIGIL(R) (modafinil) Tablets [C-IV], GABITRIL(R) (tiagabine hydrochloride) and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II], and more than 20 products internationally. Further information about Cephalon and full prescribing information on its U.S. products is available at http://www.cephalon.com/ or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,”"estimate,”"expect,”"project,”"intend,”"plan,”"believe” or other words and terms of similar meaning. Cephalon’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Cephalon, Inc.

CONTACT: Robert W. Grupp, Cephalon, +1-610-738-6402,rgrupp@cephalon.com

Web site: http://www.cephalon.com/

Company News On-Call: http://www.prnewswire.com/comp/134563.html